Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 16

1.

The immune-related role of BRAF in melanoma.

Tomei S, Bedognetti D, De Giorgi V, Sommariva M, Civini S, Reinboth J, Al Hashmi M, Ascierto ML, Liu Q, Ayotte BD, Worschech A, Uccellini L, Ascierto PA, Stroncek D, Palmieri G, Chouchane L, Wang E, Marincola FM.

Mol Oncol. 2015 Jan;9(1):93-104. doi: 10.1016/j.molonc.2014.07.014. Epub 2014 Aug 6.

2.

Identification of a novel nidovirus in an outbreak of fatal respiratory disease in ball pythons (Python regius).

Uccellini L, Ossiboff RJ, de Matos RE, Morrisey JK, Petrosov A, Navarrete-Macias I, Jain K, Hicks AL, Buckles EL, Tokarz R, McAloose D, Lipkin WI.

Virol J. 2014 Aug 8;11:144. doi: 10.1186/1743-422X-11-144.

3.

Melanoma NOS1 expression promotes dysfunctional IFN signaling.

Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, Slingluff CL Jr, Lee PP, Rosenberg SA, Alter H, Yao K, Wang E, Marincola FM.

J Clin Invest. 2014 May;124(5):2147-59. Epub 2014 Apr 1.

4.

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.

Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG, Sommariva M, Sertoli MR, Simon R, Wang E, Rosenberg SA, Marincola FM.

Br J Cancer. 2013 Oct 29;109(9):2412-23. doi: 10.1038/bjc.2013.557. Epub 2013 Oct 15.

5.

IRF-1 responsiveness to IFN-╬│ predicts different cancer immune phenotypes.

Murtas D, Maric D, De Giorgi V, Reinboth J, Worschech A, Fetsch P, Filie A, Ascierto ML, Bedognetti D, Liu Q, Uccellini L, Chouchane L, Wang E, Marincola FM, Tomei S.

Br J Cancer. 2013 Jul 9;109(1):76-82. doi: 10.1038/bjc.2013.335. Epub 2013 Jun 27.

6.

A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.

Wang E, Zhao Y, Monaco A, Uccellini L, Kirkwood JM, Spyropoulou-Vlachou M, Panelli MC, Marincola FM, Gogas H.

PLoS One. 2012;7(7):e40805. doi: 10.1371/journal.pone.0040805. Epub 2012 Jul 24.

7.

IRF5 gene polymorphisms in melanoma.

Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, Rosenberg SA, Marincola FM.

J Transl Med. 2012 Aug 21;10:170. doi: 10.1186/1479-5876-10-170.

8.

A genetic inference on cancer immune responsiveness.

Wang E, Uccellini L, Marincola FM.

Oncoimmunology. 2012 Jul 1;1(4):520-525.

9.

Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population.

Tomei S, Adams S, Uccellini L, Bedognetti D, De Giorgi V, Erdenebileg N, Ascierto ML, Reinboth J, Liu Q, Bevilacqua G, Wang E, Mazzanti C, Marincola FM.

Med Oncol. 2012 Dec;29(5):3456-61. doi: 10.1007/s12032-012-0255-3. Epub 2012 May 22.

10.

The stable traits of melanoma genetics: an alternate approach to target discovery.

Spivey TL, De Giorgi V, Zhao Y, Bedognetti D, Pos Z, Liu Q, Tomei S, Ascierto ML, Uccellini L, Reinboth J, Chouchane L, Stroncek DF, Wang E, Marincola FM.

BMC Genomics. 2012 Apr 26;13:156. doi: 10.1186/1471-2164-13-156.

11.

HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations.

Uccellini L, Tseng FC, Monaco A, Shebl FM, Pfeiffer R, Dotrang M, Buckett D, Busch MP, Wang E, Edlin BR, Marincola FM, O'Brien TR.

Hepatology. 2012 Jul;56(1):86-94. doi: 10.1002/hep.25652. Epub 2012 Jun 1.

12.

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68.

Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG, Pos Z, Roychoudhuri R, Di Pasquale G, Bedognetti D, Uccellini L, Rossano F, Ascierto PA, Stroncek DF, Restifo NP, Wang E, Szalay AA, Marincola FM.

BMC Cancer. 2011 Oct 19;11:451. doi: 10.1186/1471-2407-11-451.

13.

Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis.

Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang E, Marincola FM, Bedognetti D.

J Transl Med. 2011 Oct 12;9:174. doi: 10.1186/1479-5876-9-174.

14.

An immunologic portrait of cancer.

Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey TL, Murtas D, Uccellini L, Ayotte BD, Stroncek DF, Chouchane L, Manjili MH, Wang E, Marincola FM.

J Transl Med. 2011 Aug 29;9:146. doi: 10.1186/1479-5876-9-146. Review.

15.

Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era.

Bedognetti D, Zoppoli G, Sertoli MR, Zanardi E, Blandini P, Uccellini L, Boccardo F, Andreoli GB, Ghio R, Racchi O, Ferrarini M, De Maria A.

Int J Hematol. 2010 Mar;91(2):342-4; author reply 345-6. doi: 10.1007/s12185-010-0522-z. Epub 2010 Feb 27. No abstract available.

PMID:
20191334
16.

Antitumor vaccines, immunotherapy and the immunological constant of rejection.

Wang E, Monaco A, Monsurr├│ V, Sabatino M, Pos Z, Uccellini L, Wang J, Worschech A, Stroncek DF, Marincola FM.

IDrugs. 2009 May;12(5):297-301. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk